Asset Details
Do you wish to reserve the book?
Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury
Do you wish to request the book?
Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury
2022
Overview
High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is present in almost all cells and regulates the activity of innate immune responses in both intracellular and extracellular settings. Current evidence suggests that HMGB1 plays a pivotal role in human pathological and pathophysiological processes such as the inflammatory response, immune reactions, cell migration, aging, and cell death. Sepsis is a systemic inflammatory response syndrome (SIRS) that occurs in hosts in response to microbial infections with a proven or suspected infectious etiology and is the leading cause of death in intensive care units worldwide, particularly in the aging population. Dysregulated systemic inflammation is a classic characteristic of sepsis, and suppression of HMGB1 may ameliorate inflammation and improve patient outcomes. Here, we focus on the latest breakthroughs regarding the roles of HMGB1 in sepsis and sepsis-related organ injury, the ways by which HMGB1 are released, and the signaling pathways and therapeutics associated with HMGB1. This review highlights recent advances related to HMGB1: the regulation of HMBG1 might be helpful for both basic research and drug development for the treatment of sepsis and sepsis-related organ injury.
Publisher
Springer Singapore,Nature Publishing Group
Subject
/ Biomedical and Life Sciences
/ Blood Coagulation Disorders - pathology
/ Cytokine Release Syndrome - pathology
/ Endoplasmic Reticulum Stress - physiology
/ Etiology
/ High mobility group proteins
/ Humans
/ Inflammation Mediators - metabolism
/ Multiple Organ Failure - drug therapy
/ Multiple Organ Failure - pathology
/ Receptor for Advanced Glycation End Products - metabolism
/ Review
/ Sepsis
/ Signal Transduction - physiology
/ Systemic inflammatory response syndrome
/ Toll-Like Receptors - metabolism
/ Vaccine
